About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

Latest News and Events
Imagion Biosystems March 2021 Investor Newsletter
March 29, 2021
Imagion Biosystems is pleased to provide its investors with its March 2021…
Imagion Receives CSIRO Federal Government Grant for Prostate Cancer Project
March 15, 2021
Imagion Biosystems is pleased to announce it is a proud recipient of an…
Imagion Biosystems 2020 Full Year Results
February 24, 2021
2020 Highlights: MagSense® HER2 breast cancer Phase I study initiated…
Quarterly Activity Report for 31 December 2020 — Appendix 4C
January 20, 2021
Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and…
Imagion Biosystems December 2020 Investor Newsletter
December 17, 2020
Imagion Biosystems is pleased to provide its investors with its December 2020…
First In-human Study Update: Study Open for Enrolment
December 16, 2020
Imagion Biosystems is pleased to announce that Monash Health has been…
Proposed Issue of Securities — Appendix 3B
November 22, 2020
Imagion Biosystems has announced a Proposed Issue of Securities. Read the…
IBX Raises $6M in Placement
November 22, 2020
Highlights: $6M raised in a heavily oversubscribed placement at 8.5c per share…
Trading Halt
November 19, 2020
The securities of Imagion Biosystems will be placed in trading halt the request…
Statement Pursuant to Listing Rule 4.7C.3
November 5, 2020
Imagion Biosystems advises that in accordance with Listing Rule 4.7C.3, and as…
New Imaging Technology for Early Detection
October 29, 2020
Early detection is critical to improving cancer survival rates. Too often, the…
Appendix C and Quarterly Activity Report
October 26, 2020
Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and…
Quarterly Activity Report and Appendix C
October 26, 2020
Imagion Biosystems has released their Quarterly Activity Report for the period…
Appendix 3Y — Change of Director’s Interest Notice
October 21, 2020
Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent…
Appendix 2A — Fully Paid Ordinary Shares
October 21, 2020
Imagion Biosystems has submitted "Appendix 2A — Application for quotation of…
Vesting of Performance Rights
October 21, 2020
Imagion Biosystems has advised that 2,500,000 performance rights have vested…
Notice Pursuant to Section 708(5)(e) of the Corporations Act 2001
October 19, 2020
Imagion Biosystems gives notice that, on 20 October 2020 the Company issued…
IBX Secures Additional Capital — Shareholders Exercise Options
October 19, 2020
Imagion Biosystems announced that it has received a total of $143,157 for the…
Imagion Biosystems Appoints Geoff Hollis as CFO
October 19, 2020
Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer.…
HREC Approval for Phase I Study
October 8, 2020
Imagion Biosystems is pleased to report that it has received approval from…
Issue of Unlisted Performance Options under EIP
October 5, 2020
Imagion Biosystems today announced "Issue of unlisted performance options under…
Corporate
governance
Imagion Biosystems and its Board of Directors is committed to maintain high levels of integrity and ethical standards in the way we conduct our business and in our corporate governance.
The Board of Directors is composed, chiefly, of non-executive directors with the Chairman having been elected by the full Board. The company is small, and accordingly, the Board has adopted those policies it deems prudent to protect the interests of our shareholders without being overly burdensome on the company.
Investor services
Investors seeking information regarding their shareholding or dividends or wishing to advise of a change of address should contact Boardroom Pty Limited at:
Boardroom Pty Limited
Level 12, 225 George Street,
Sydney, NSW, 2000
Telephone: (02) 9290 9600 Facsimile: (02) 9279 0664 or
Visit the online service at www.boardroomlimited.com.au
Boardroom Pty Limited has an online service for investors called InvestorServe. This enables investors to make online changes, view balances and transaction history, as well as obtain information about recent dividend payments and download various forms to assist in the management of their holding.
Questions?
Reach the Investor Relations department by emailing investor@imagionbio.com, and we’ll get back to you.